Nanjing CIGU Technology Corp.,LTD. (SHA:688448)

Sage Therapeutics Income Statement

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Operating Revenue	439.56	445.29	394.91	330.98	301.38	245.43
Other Revenue	33.2	33.2	18.65	13.19	10.23	5.8
Revenue	472.77	478.49	413.56	344.17	311.61	251.23
Revenue Growth (YoY)	12.35%	15.70%	20.16%	10.45%	24.03%	17.73%
Cost of Revenue	321.41	325.27	280.72	219.56	187.95	139.05
Gross Profit	151.36	153.22	132.84	124.61	123.65	112.18
Selling, General & Admin	65.76	63.84	54.77	51	46.74	45.11
Research & Development	42.6	43.87	40.33	34.85	24.23	19.78
Other Operating Expenses	-6.4	-9.25	-4.73	-3.88	-3.16	-1
Operating Expenses	116.33	113.5	104.25	91.61	72.74	65.71
Operating Income	35.03	39.72	28.59	33	50.91	46.47
Interest Expense	-0.16	-0.11	-0.17	-0.64	-0.49	-2.46
Interest & Investment Income	6.95	7.55	11.55	3.83	0.96	0.65
Currency Exchange Gain (Loss)	0.37	0.37	-0.01	-	-	-
Other Non Operating Income (Expenses)	-0.04	-0.02	-0.61	0.11	-0.13	0.58
EBT Excluding Unusual Items	42.14	47.5	39.34	36.3	51.26	45.25
Gain (Loss) on Sale of Investments	-	-	-	-	-0.12	-
Gain (Loss) on Sale of Assets	-0.09	-0.1	0.03	0.32	-	0.02
Asset Writedown	0.16	-	-	-	-	-
Other Unusual Items	7.42	7.42	11.05	13.65	15.9	10.03
Pretax Income	49.63	54.83	50.42	50.27	67.03	55.3
Income Tax Expense	3.67	3.64	2.36	2.63	7.27	7.05
Earnings From Continuing Operations	45.96	51.18	48.06	47.64	59.76	48.25
Minority Interest in Earnings	0.45	0.32	-	-	-	-
Net Income	46.41	51.5	48.06	47.64	59.76	48.25
Net Income to Common	46.41	51.5	48.06	47.64	59.76	48.25
Net Income Growth	-7.18%	7.16%	0.90%	-20.29%	23.87%	17.31%
Shares Outstanding (Basic)	72	72	72	58	53	51
Shares Outstanding (Diluted)	72	72	72	58	53	51
Shares Change (YoY)	-3.57%	-0.29%	23.49%	8.88%	3.96%	7.33%
EPS (Basic)	0.65	0.72	0.67	0.82	1.12	0.94
EPS (Diluted)	0.65	0.72	0.67	0.82	1.12	0.94
EPS Growth	-3.75%	7.46%	-18.29%	-26.79%	19.15%	9.30%
Free Cash Flow	-46.78	-5.39	-85.94	45.8	-17.59	38.96
Free Cash Flow Per Share	-0.65	-0.07	-1.20	0.79	-0.33	0.76
Dividend Per Share	0.300	0.300	0.450	-	-	-
Dividend Growth	-33.33%	-33.33%	-	-	-	-
Gross Margin	32.02%	32.02%	32.12%	36.21%	39.68%	44.65%
Operating Margin	7.41%	8.30%	6.91%	9.59%	16.34%	18.50%
Profit Margin	9.82%	10.76%	11.62%	13.84%	19.18%	19.20%
Free Cash Flow Margin	-9.90%	-1.13%	-20.78%	13.31%	-5.64%	15.51%
EBITDA	46.56	51.52	41.48	45.82	62.87	56.35
EBITDA Margin	9.85%	10.77%	10.03%	13.31%	20.18%	22.43%
D&A For EBITDA	11.53	11.8	12.89	12.82	11.96	9.88
EBIT	35.03	39.72	28.59	33	50.91	46.47
EBIT Margin	7.41%	8.30%	6.91%	9.59%	16.34%	18.50%
Effective Tax Rate	7.39%	6.65%	4.67%	5.24%	10.85%	12.76%
Revenue as Reported	472.77	478.49	413.56	344.17	311.61	251.23

Updated Feb 25, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.